Markus Hoffmann, Andreas Mock, Elgar Susanne Quabius, Anne Letsch, Frauke Nees, Silke Tribius, Susanne Wiegand
Human papillomavirus (HPV)-associated cancers are increasingly recognized as biologically heterogeneous diseases shaped by complex interactions between viral activity, host biology, tissue context, and behavioral factors. Marked sex disparities in incidence, viral persistence, immune response, and clinical outcome further emphasize this complexity. Although HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) is generally associated with a favorable prognosis, accumulating evidence indicates substantial heterogeneity across anatomical sites, patient populations, and sexes. Importantly, these differences likely arise long before clinically detectable malignancy, beginning with viral exposure, mucosal interaction, immune adaptation, and persistent infection. In this conceptual perspective, we propose that HPV positivity represents the biological starting point rather than the complete biological explanation of HPV-associated carcinogenesis. HPV-associated cancers arise through dynamic interactions among viral biology, sex-related host factors, immune context, tissue-specific microenvironments, and gender-associated behavioral and healthcare-related variables. Host-associated factors, including smoking-related mucosal alterations, comorbidity, immune competence, and the limitations of surrogate biomarkers such as p16 immunohistochemistry, may substantially modify tumor evolution and clinical interpretation despite identical HPV status. We argue that many observed sex disparities and prognostic differences reflect multidimensional interactions between viral, biological, behavioral, and contextual determinants rather than viral effects alone. Integrating these dimensions into a unified biological framework may improve patient stratification, prognostic assessment, clinical trial design, and future precision oncology.